-
Merck KGaA Launches First GMP Cell Culture Medium Production Line in China
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of its first Good Manufacturing Practice (GMP) compliant cell culture medium (CCM) production line in China. This strategic expansion into the Chinese market is a response to the growing demand for high-quality, customized CCM solutions. Merck’s…
-
Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center
•
Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a significant expansion of its life science distribution center in Germany, increasing the facility’s size by 25,000 square meters. This €180 million ($194 million) investment bolsters the center’s capabilities with additional filling lines and global distribution…
-
Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant
•
Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a new bioprocessing plant in South Korea with a groundbreaking ceremony. This initiative represents Merck’s largest single investment in the Asia-Pacific region, exceeding USD 300 million. The construction follows a memorandum of understanding with the Ministry…
-
Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination
•
Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered into a partnership with US-based Aulos Bioscience. This collaboration aims to advance the clinical development of Merck’s anti-PD-L1 drug Bavencio (avelumab) in combination with Aulos’s anti-IL-2 antibody candidate, AU-007. The financial details of the agreement…
-
Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates
•
German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life Sciences’ research unit, Caris Discovery, to uncover novel oncology targets and develop first-in-class antibody-drug conjugates (ADCs). The partnership aims to harness Caris’ precision medicine expertise and Merck’s ADC technology to accelerate the discovery and development…
-
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
•
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the M Lab Collaboration Center in Shanghai, which is the largest among its global network of 10 such centers. This significant expansion represents an additional investment of EUR 14 million, resulting in the addition of a…
-
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
•
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global net sales for the fiscal year 2023, amounting to €21.0 billion ($23.0 billion). This contraction was partially attributed to the adverse impact of foreign exchange rates. The company’s Healthcare division, however, posted a 2.7% increase…
-
Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show
•
Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this week unveiled new clinical data for its cytotoxic drug Mavenclad (cladribine) in the treatment of highly active relapsing multiple sclerosis (RMS). The results indicate that over 95% of participants noted clinically meaningful improvements in cognitive…
-
German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research
•
Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub in Singapore, marking its first such initiative outside of Europe and the US. This new digital hub will leverage collaboration platforms Syntropy and Athinia to enhance data analytics capabilities, aiming to spur innovation and research…
-
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The…
-
Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China
•
Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the second phase of its new EUR 29 million (USD 32 million) Biologics Testing Center in China. This expansion adds 1,500 square meters to the lab, which initially opened its doors last year. Marking the first…
-
Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches
•
Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this week unveiled its strategic plans for the US healthcare market. The company, which currently commercializes two cancer treatments in the US, is gearing up to launch two additional drugs by 2025. Furthermore, Merck anticipates continuing…
-
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
•
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023, revealing a 4.1% year-on-year (YOY) decline in organic sales, totaling EUR 5.2 billion (USD 5.5 billion) for the three-month period. The results highlight a challenging environment, with only the Healthcare division showing growth. The Healthcare…
-
AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit
•
Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has reportedly taken on a new role at German pharmaceutical giant Merck KGaA (ETR: MRK). He has been appointed as the vice-president of Merck’s China medicine and health business, where he will lead the Cardiovascular, Metabolic,…
